Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan

2019 ◽  
Vol 84 (5) ◽  
pp. 1051-1058
Author(s):  
Mayu Yunokawa ◽  
Shinsuke Sasada ◽  
Yae Takehara ◽  
Kenta Takahashi ◽  
Tatsunori Shimoi ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Older Adult ◽  
Real World ◽  
Initial Treatment ◽  
Treatment Strategies ◽  
Adult Patients ◽  
Real World Data ◽  
World Data

Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data

2020 ◽  
Vol 146 (5) ◽  
pp. 1335-1341
Author(s):  
Mayumi Kobayashi Kato ◽  
Mayu Yunokawa ◽  
Seiko Bun ◽  
Tatsunori Shimoi ◽  
Kan Yonemori ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Older Adult ◽  
Real World ◽  
Treatment Strategies ◽  
Recurrent Ovarian Cancer ◽  
Adult Patients ◽  
Real World Data ◽  
World Data

scholarly journals Burden Of Disease And Health Care Costs Of Adult Patients With Severe Refractory Asthma In A Big Real-World Data Base (Arco)

2016 ◽  
Vol 19 (3) ◽  
pp. A112
Author(s):  
A Pedrini ◽  
E Rossi ◽  
S Calabria ◽  
L Dondi ◽  
I Esposito ◽  
...  
Keyword(s):  
Health Care ◽  
Data Base ◽  
Health Care Costs ◽  
Real World ◽  
Burden Of Disease ◽  
Adult Patients ◽  
Real World Data ◽  
World Data ◽  
Care Costs ◽  
Refractory Asthma

PIN79 Real-World DATA Analysis of Antiretroviral Treatment for HIV-Infected Adult Patients in Ukraine

2021 ◽  
Vol 24 ◽  
pp. S120-S121
Author(s):  
O. Vysotska ◽  
O. Piniazhko ◽  
V. Vysotskyi ◽  
A. Masheiko ◽  
V. Serediuk ◽  
...  
Keyword(s):  
Data Analysis ◽  
Real World ◽  
Antiretroviral Treatment ◽  
Adult Patients ◽  
Real World Data ◽  
World Data ◽  
Infected Adult

scholarly journals Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data

2021 ◽  
Vol 11 (1) ◽  
pp. 48 ◽  
Author(s):  
Felicitas Oberndorfer ◽  
Sarah Moling ◽  
Leonie Annika Hagelkruys ◽  
Christoph Grimm ◽  
Stephan Polterauer ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Real World ◽  
Treatment Decisions ◽  
Molecular Profiling ◽  
Genetic Alterations ◽  
Classification Systems ◽  
Molecular Profile ◽  
Daily Routine ◽  
Real World Data ◽  
World Data

Recently, guidelines for endometrial cancer (EC) were released that guide treatment decisions according to the tumors’ molecular profiles. To date, no real-world data regarding the clinical feasibility of molecular profiling have been released. This retrospective, monocentric study investigated the clinical feasibility of molecular profiling and its potential impact on treatment decisions. Tumor specimens underwent molecular profiling (testing for genetic alterations, (immune-)histological examination of lymphovascular space invasion (LVSI), and L1CAM) as part of the clinical routine and were classified according to the European Society for Medical Oncology (ESMO) classification system and to an integrated molecular risk stratification. Shifts between risk groups and potential treatment alterations are described. A total of 60 cases were included, of which twelve were excluded (20%), and eight of the remaining 48 were not characterized (drop-out rate of 16.7%). Molecular profiling revealed 4, 6, 25, and 5 patients with DNA polymerase-epsilon mutation, microsatellite instability, no specific molecular profile, and TP53 mutation, respectively. Three patients had substantial LVSI, and four patients showed high L1CAM expression. Molecular profiling took a median of 18.5 days. Substantial shifts occurred between the classification systems: four patients were upstaged, and 19 patients were downstaged. Molecular profiling of EC specimens is feasible in a daily routine, and new risk classification systems will change treatment decisions substantially.

27434 Early trends of disease improvement in adult patients with atopic dermatitis treated with dupilumab: Real-world data from the PROSE registry

2021 ◽  
Vol 85 (3) ◽  
pp. AB32
Author(s):  
Jerry Bagel ◽  
Gil Yosipovitch ◽  
David M. Pariser ◽  
Robert Y. Lin ◽  
Haixin Zhang ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Real World ◽  
Adult Patients ◽  
Real World Data ◽  
World Data

scholarly journals Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan

2020 ◽  
Vol 10 (1) ◽  
pp. 105
Author(s):  
Keiichi Akizuki ◽  
Hitoshi Matsuoka ◽  
Takanori Toyama ◽  
Ayako Kamiunten ◽  
Masaaki Sekine ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Real World ◽  
Initial Treatment ◽  
Staging System ◽  
Novel Agents ◽  
Real World Data ◽  
World Data

The prognosis of multiple myeloma (MM) has improved with the introduction of novel agents. These data are largely derived from clinical trials and might not reflect real-world patient outcomes accurately. We surveyed real-world data from 284 patients newly diagnosed with MM between 2010 and 2018 in Miyazaki Prefecture. The median follow-up period was 32.8 months. The median age at diagnosis was 71 years, with 68% of patients aged >65 years. The International Staging System (ISS) stage at diagnosis was I in 18.4% of patients, II in 34.1%, and III in 47.5%. Bortezomib-containing regimens were preferred as initial treatment; they were used in 147 patients (51.8%). In total, 80% of patients were treated with one or more novel agents (thalidomide, lenalidomide, or bortezomib). Among 228 patients who were treated with novel agents as an initial treatment, the overall response rate (partial response (PR) or better) to initial treatment was 78.4%, and the median time to next treatment (TTNT) was 11.6 months. In the multivariate analysis, PR or better responses to initial treatment were independently favorable prognostic factors for TTNT. The median survival time after initial therapy for patients with novel agents was 56.4 months and 3-year overall survival (OS) was 70.4%. In multivariate analysis, ISS stage I/II disease and PR or better response to initial treatment, and autologous stem cell transplantation (ASCT) were identified as independent prognostic factors for overall survival (OS).

Sign in / Sign up

Export Citation Format

Share Document